BRAF and neuroendocrine carcinoma: While the experience of genetics-guided therapy is limited in NEC, the European Neuroendocrine Tumor Society (ENETS) 2023 guidelines (5) recommend that BRAF-inhibitor combinations should be considered as a possible treatment in case of BRAF-mutated tumors.